免疫检查点阻断通过扩增效应 CD8⁺ T 细胞克隆增强淋巴细胞清除性化疗诱导的抗肿瘤免疫
Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy-Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
黑色素瘤中的 TIL：相似的方法、不同的结果、未解的问题
英文原题：TIL in Melanoma-Similar Approaches, Different Results, Unanswered Questions.
查看英文原题
TIL in Melanoma-Similar Approaches, Different Results, Unanswered Questions.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
既往接受抗 PD-1 和/或 BRAF 靶向治疗，与TIL（肿瘤浸润淋巴细胞）疗法在转移性黑色素瘤中的有限活性相关。近期关于 TIL 和抗 PD-1 作用机制的新认识，为理解不同试验或人群之间的结局差异奠定了基础，也为开发更优产品提供了路线图。参见 Seitter 等人相关文章，第 5289 页。
展开英文摘要原文
Prior treatment with anti-PD-1 and/or BRAF-targeted therapies was associated with limited activity of tumor infiltrating lymphocytes (TIL) in metastatic melanoma. Recent insights into mechanisms of action for TIL and anti-PD-1 provide the foundation for understanding differences in outcomes in different trials or populations, and a roadmap for developing improved products. See related article by Seitter et al., p. 5289.
论文信息
- 作者
- Sznol M
- 单位
- Medical Oncology, Yale University School of Medicine, New Haven, Connecticut.
- 文献类型
- 评论
- 期刊
- Clinical cancer research : an official journal of the American Association for Cancer Research2021 Oct 1
- 原文标识
- PubMed 34413160 · DOI 10.1158/1078-0432.CCR-21-2450